Table 4.

Multivariate Cox regression analysis for independent factors of PAL treatment.

Characteristic	HR	95% CI	p-Value
Ki-67 status
≥30% vs. <15%	1.73	1.11–2.70	0.015
Sensitivity to ET
Primary resistance vs. secondary resistance	1.61	1.08–2.38	0.018
Liver metastases
Yes vs. no	2.22	1.41–3.48	0.001
Number of sites of metastasis
≥2 vs. <2	0.66	0.45–0.95	0.028
LOT (line of therapy) of ET
1 L vs. ≥2 L	0.65	0.44–0.96	0.031
Endocrine partner
Aromatase inhibitors vs. fulvestrant	0.71	0.50–0.99	0.047